CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large.
CARLSBAD, Calif., Feb. 1, 2024 /PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia. Achondroplasia is the most
/PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that.
Carlsbad-based Tyra Biosciences ,a company developing precision medicines for targeting Fibroblast Growth Factor Receptor (FGFR) biology, has raised $200M in a private placement (PIPE). The publicly listed compan